Tagrisso (Osimertinib) Cost in the U.S.: Insurance, Assistance & Safe Access Guide
Expert article by Dr. Charles drew, Lead Pharmaceutical Content Specialist
Medically reviewed by Ivermectinkart pharmacy on 09/09/2026
Introduction
The Tagrisso cost in the U.S. can be difficult to understand because the pharmacy price and the amount a patient actually pays are often very different. Tagrisso (osimertinib) is a prescription targeted cancer medicine from AstraZeneca used for specific forms of non-small cell lung cancer (NSCLC) with certain epidermal growth factor receptor, or EGFR, mutations. Current U.S. cash-price references place a 30-tablet supply at roughly $18,000 or more before insurance or assistance, although retail prices can change and vary by pharmacy. Insurance may substantially reduce that amount, but prior authorization, specialty-pharmacy requirements, deductibles, and coinsurance can still affect what a patient pays.
Medicare beneficiaries have additional protections in 2026, including a $2,100 annual out-of-pocket limit for Part D-covered drugs. This guide explains Tagrisso pricing, insurance coverage, manufacturer assistance, Medicare options, and how to obtain this cancer medicine through legitimate U.S. channels.
How Much Does Tagrisso Cost in the U.S.?
Without insurance or financial assistance, Tagrisso can cost roughly $18,000 or more for 30 tablets at current retail cash-price estimates. One current U.S. price reference lists approximately $18,278 for 30 tablets of either the 40-mg or 80-mg strength, but pharmacy prices fluctuate and this figure should be treated as an estimate rather than a guaranteed price.
The price you personally pay can be dramatically different. A patient with commercial insurance and manufacturer assistance might have a very low copay, while someone without coverage or assistance could face a much larger bill.
Why the advertised Tagrisso price may differ from what a U.S. patient actually pays
Cost situation | Possible patient cost | What affects the amount |
Cash purchase without insurance | Roughly $18,000+ per 30 tablets based on current retail estimates | Pharmacy pricing and discounts |
Commercial insurance | Varies widely | Formulary, deductible, copay or coinsurance, prior authorization |
Eligible commercial insurance + manufacturer savings | May be as little as $0 per month | Program eligibility, terms and savings limits |
Medicare Part D | Plan-specific until annual limit is reached | Formulary, deductible, cost sharing, Extra Help and other assistance |
AZ&Me assistance | $0 for the AstraZeneca medicine for qualifying patients | Insurance status, income and other eligibility requirements |
The most useful number is therefore not simply the retail price. It is the estimated out-of-pocket cost after your specific insurance and any assistance for which you qualify.
A five-figure Tagrisso retail price does not automatically mean a patient will personally owe that amount. Before paying cash, ask the insurer, oncology team, specialty pharmacy, and applicable assistance programs to determine the actual out-of-pocket cost.
Why Is Tagrisso So Expensive?
Tagrisso is a branded targeted cancer therapy rather than a conventional low-cost generic medicine. It belongs to a group of medicines called EGFR tyrosine kinase inhibitors, which target abnormal EGFR signaling that can drive certain lung cancers.
The medicine is used only in appropriate patients based on the cancer's characteristics. Depending on the FDA-approved indication, EGFR mutation testing helps determine whether the tumor has a mutation for which osimertinib is indicated.
Unlike a medicine that may be needed for only a few days, cancer therapy can also involve repeated monthly prescription fills. That makes both the monthly cost and the patient's cumulative out-of-pocket exposure important.
A high published price does not necessarily represent what insurers ultimately pay after negotiated arrangements, nor does it represent every patient's pharmacy bill. The retail or list-price concept, insurer-negotiated costs, manufacturer assistance, and patient cost sharing should therefore be kept separate.
Does Insurance Cover Tagrisso?
Many insurance plans may cover Tagrisso when it is medically appropriate, but coverage is plan-specific and should never be assumed. Because Tagrisso is a high-cost specialty cancer medication, an insurer may require documentation before approving payment.
Common coverage requirements can include:
confirmation of the cancer diagnosis;
documentation of the relevant EGFR mutation;
an FDA-approved or otherwise plan-covered treatment indication;
prior authorization from the insurer;
a quantity limit;
use of a designated specialty pharmacy; or
periodic authorization renewal.
Some formularies specifically classify Tagrisso as a specialty drug and apply prior authorization and quantity restrictions. These requirements can vary substantially between insurers and even between different plans from the same insurer.
What is prior authorization for Tagrisso?
Prior authorization means the insurance company reviews specified clinical information before agreeing to cover the prescription. It is not the same as the oncologist writing the prescription.
The oncology office may need to submit the diagnosis, pathology information, EGFR test results, previous treatments, treatment stage, and other documentation requested by the plan.
If authorization is delayed or denied, patients should not simply abandon prescribed cancer treatment or replace it with a product obtained from an unverified seller. Ask the oncology office and insurer what information is missing, whether an appeal or reconsideration is available, and whether temporary access assistance may apply.
Why can an insured patient still face a large bill?
Insurance coverage does not necessarily mean a small fixed copay. Specialty drugs may be subject to deductibles or coinsurance, where the patient owes a percentage of the covered cost.
Your amount can depend on:
whether the deductible has been met;
the drug's formulary tier;
fixed copay versus percentage coinsurance;
whether the required specialty pharmacy is used;
annual out-of-pocket protections; and
whether copay or patient assistance is available.
For that reason, ask for an actual benefit investigation rather than assuming that “covered” means “affordable.”
How Can Commercially Insured Patients Lower Tagrisso Costs?
Eligible patients with commercial insurance may qualify for AstraZeneca's Tagrisso Co-pay Savings Program. The manufacturer currently states that qualifying commercially insured patients may pay as little as $0 per month, although restrictions, maximum savings limits, and other terms apply.
The Tagrisso financial assistance information explains the manufacturer's current options for commercially insured, government-insured, and uninsured patients.
Importantly, “as little as $0” is not a promise that every commercially insured patient will pay nothing. Eligibility must be confirmed under the current program terms.
Manufacturer copay programs also generally operate differently from programs for people with Medicare or other government coverage. Do not assume that a commercial copay card can be used with Medicare.
What should you ask your insurance company?
A short call to your insurer or specialty pharmacy can clarify several issues before the first prescription is filled. Ask:
Is Tagrisso on my current formulary?
Is prior authorization required?
Is there a quantity limit?
Must I use a particular specialty pharmacy?
What is my expected cost for a 30-day supply?
Does that estimate include my remaining deductible?
What happens to my cost after I reach my plan's out-of-pocket limit?
If coverage is denied, what is the appeal process?
Your oncology practice may also have a financial navigator, social worker, pharmacist, or patient-access specialist who can help coordinate these questions.
What Does Tagrisso Cost With Medicare in 2026?
For a Medicare beneficiary, the exact Tagrisso cost depends on the person's Part D coverage and whether Tagrisso is covered by that plan. A major 2026 protection is that annual out-of-pocket spending for Part D-covered prescription drugs is capped at $2,100. Once that threshold is reached, the beneficiary has no additional out-of-pocket costs for covered Part D drugs for the remainder of that calendar year.
The Medicare 2026 prescription drug out-of-pocket limit explains the current $2,100 annual cap.
This cap applies across covered Part D prescriptions rather than setting a $2,100 price specifically for Tagrisso. Premiums and costs that do not count toward the Part D out-of-pocket calculation should not be confused with the cap.
Can Medicare patients spread their prescription costs across the year?
Yes. The Medicare Prescription Payment Plan allows people with Medicare drug coverage to spread their out-of-pocket prescription costs over the calendar year rather than necessarily paying a large amount at the pharmacy early in the year.
However, the program does not reduce the total drug cost owed. Medicare specifically explains that it is a payment-management option, not a discount program.
For someone taking an expensive covered medicine, spreading payments may make monthly budgeting easier. The appropriate choice depends on when prescription costs occur during the year.
What is Medicare Extra Help?
Extra Help is a federal program that lowers Medicare drug costs for people who meet income and resource requirements. For 2026, Medicare lists income and resource thresholds and states that qualifying beneficiaries pay no premium or deductible under Extra Help and pay no more than specified amounts for covered prescriptions.
Someone facing high Tagrisso costs who has limited income or resources should therefore check eligibility rather than assuming they cannot afford treatment.
What Tagrisso Patient Assistance Programs Are Available?
AstraZeneca provides several support pathways, but the appropriate program depends on insurance status and eligibility. Manufacturer assistance should be checked using current official program requirements because terms can change from year to year.
AZ&Me Prescription Savings Program
The AZ&Me Prescription Savings Program provides AstraZeneca medicines at no cost to qualifying people. AstraZeneca's current 2026 eligibility information states that applicants generally must live in the United States, receive treatment from a U.S.-licensed health care provider, meet applicable insurance requirements, and satisfy the program's income criteria.
For 2026, AZ&Me eligibility requirements state that annual adjusted gross household income for Primary and Specialty medications must generally be at or below 300% of the Federal Poverty Level.
Eligibility is more detailed than income alone. For example, the program generally excludes people with commercial insurance, while Medicare beneficiaries face additional requirements. AstraZeneca also states that eligible Specialty and Rare Disease Medicare applicants may have to pursue certain independent nonprofit assistance before completing AZ&Me enrollment.
Independent charitable assistance
Some independent nonprofit foundations provide assistance with medication copays or other treatment-related costs when funding is available. Eligibility, covered diagnoses, income criteria, and whether a fund is open can change.
AstraZeneca Access 360 can provide information about independent charitable foundations but explicitly states that it cannot guarantee assistance.
This distinction matters. A foundation appearing on a resource list does not mean that it currently has an open lung-cancer fund or that a particular patient will qualify.
Tagrisso cost-assistance routes to check based on insurance status
Patient situation | Assistance route to investigate | Important limitation |
Commercial insurance | Tagrisso Co-pay Savings Program | Eligibility and maximum savings terms apply |
Medicare Part D | Part D $2,100 annual out-of-pocket limit in 2026 | Applies to Part D-covered drugs and qualifying out-of-pocket spending |
Medicare with limited income/resources | Medicare Extra Help | Income/resource eligibility applies |
Eligible uninsured patient | AZ&Me | Insurance, income and other program requirements apply |
Eligible Medicare patient needing additional help | AZ&Me and independent nonprofit assistance pathways | Additional 2026 program requirements may apply |
High pharmacy bill early in year | Medicare Prescription Payment Plan, if enrolled in Part D | Spreads costs; does not lower the total amount owed |
How Can You Access Tagrisso Safely in the U.S.?
Tagrisso is a prescription cancer medicine and should be obtained through the oncology and legitimate pharmacy system. A very low online price should not outweigh concerns about product authenticity, storage, dispensing oversight, or whether the medicine is appropriate for the patient's cancer.
A safer access process is to:
Have the diagnosis and relevant biomarker results reviewed by the oncology team.
Obtain a prescription from the treating clinician.
Complete any required insurance prior authorization.
Confirm the required specialty pharmacy.
Ask for a written or documented estimate of the out-of-pocket cost.
Screen for manufacturer, Medicare, or independent assistance before paying a large cash price.
Obtain the medicine from a legitimate U.S. pharmacy and follow the prescribed treatment plan.
Do not substitute an unfamiliar product marketed as “generic osimertinib” simply because it costs less online. Product approval and availability differ between countries, and a medicine sold overseas should not automatically be assumed to be an FDA-approved U.S. substitute for Tagrisso.
Cost concerns are also a reason to contact the oncology team—not a reason to ration tablets, skip doses, split tablets, change the schedule, or stop treatment independently.
Tagrisso Safety and When to Contact Your Oncology Team
Tagrisso requires medical supervision because it can cause serious adverse reactions as well as more common side effects. Financial difficulty should be discussed promptly with the oncology team so that a patient does not make unsupervised changes to cancer treatment.
Contact the treating team if you are considering stopping Tagrisso because of cost, cannot obtain the next supply, or have missed doses because access was interrupted. The oncology office may be able to coordinate the insurer, specialty pharmacy, manufacturer support services, or other assistance.
Also seek prompt medical advice for new or worsening symptoms during treatment, particularly breathing problems, symptoms suggesting a heart problem, significant eye symptoms, or severe skin reactions. Treatment decisions, dose interruptions, and dose reductions should be made by the treating clinician rather than based on online dosing advice.
Conclusion
The Tagrisso cost in the U.S. can exceed roughly $18,000 for a 30-tablet supply at current cash-price estimates, but that figure does not tell you what an individual patient will actually pay. Commercial insurance, manufacturer copay support, AZ&Me, Medicare Extra Help, and the 2026 Medicare Part D $2,100 out-of-pocket limit may substantially change the financial picture for eligible patients.
If Tagrisso has been prescribed, ask the oncology team or specialty pharmacy to investigate coverage and assistance before paying a large cash price. Do not alter or stop cancer treatment because of cost without speaking with the treating oncology team, and obtain prescription cancer medicines only through legitimate pharmacy channels.
Frequently Asked Questions
1 . How much is a 30-day supply of Tagrisso without insurance?
A current U.S. retail-price reference estimates about $18,278 for 30 Tagrisso tablets, although cash prices can vary and change. This is not necessarily what an insured or assistance-eligible patient pays. Always request a current pharmacy-specific quote before making financial decisions.
2 . Does insurance usually pay for Tagrisso?
Insurance may cover Tagrisso when the treatment meets the plan's medical and coverage criteria. Prior authorization, biomarker documentation, quantity limits, and specialty-pharmacy requirements may apply. Ask the insurer for a benefit investigation showing your expected out-of-pocket cost rather than relying only on whether the medicine is listed as covered.
3 . Can I get Tagrisso for $0 with commercial insurance?
Eligible commercially insured patients may pay as little as $0 per month through AstraZeneca's current copay savings program. Eligibility restrictions and maximum savings limits apply, so $0 is not guaranteed for every patient. Current terms should be confirmed before treatment or each enrollment period.
4 . How much can a Medicare patient pay for Tagrisso in 2026?
The exact amount depends on the Part D plan, but total annual out-of-pocket spending for Part D-covered drugs is capped at $2,100 in 2026. After reaching that limit, beneficiaries pay $0 for covered Part D drugs for the rest of the calendar year.
5 . Can uninsured patients get help paying for Tagrisso?
Qualifying patients may receive AstraZeneca medicines at no cost through AZ&Me. The program has insurance, residency, treatment, income, and other eligibility requirements; for Specialty and Primary medicines, the 2026 income threshold is generally 300% of the Federal Poverty Level.
6 . Should I buy cheaper osimertinib from an overseas website?
Do not assume an inexpensive overseas product is equivalent to FDA-approved Tagrisso sold through legitimate U.S. pharmacies. Approval, manufacturing oversight, supply-chain protections, and dispensing requirements can differ. If cost is the problem, ask your oncology team or specialty pharmacy about insurance appeals and verified assistance programs before seeking alternatives.
Comments